Q-omics provides the consensus-scored METTL18 profile across patient tissues and cancer cell-line models. METTL18 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, METTL18 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, METTL18 RNA expression shows 19,078 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, LIHC, and ACC as cancer lineages where METTL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL18 survival associations across molecular data types. METTL18 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL18 RNA expression–survival associations across cancer types. High METTL18 expression shows unfavorable associations in KIRP, LIHC, ACC, SCLC and KICH, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for METTL18 RNA expression.
This table summarizes METTL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METTL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL18 shows lower tumor expression in KICH and higher tumor expression in LIHC, HNSC, BRCA, LUAD and BLCA. The LIHC box plot shows higher METTL18 RNA expression in tumor versus normal tissue (log2 FC = +1.620, t-test p < 0.001).
This table shows molecular features associated with METTL18 in patient tissues and cancer cell lines. In patient samples, METTL18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
